Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics (NQ: MRTX )

53.09 +2.03 (+3.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 933,779
Open 50.73
Bid (Size) 52.30 (2)
Ask (Size) 60.32 (1)
Prev. Close 51.06
Today's Range 50.73 - 53.60
52wk Range 32.96 - 124.81
Shares Outstanding 51,623,193
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Shares of Zai Lab Soared This Week
A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company. 
Via The Motley Fool
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga

Performance

YTD
+13.80%
+13.80%
1 Month
+24.42%
+24.42%
3 Month
-21.14%
-21.14%
6 Month
-19.30%
-19.30%
1 Year
-53.00%
-53.00%

More News

Read More
SKLZ Stock Alert: Will Skillz Shares Get Delisted?
Via InvestorPlace
Why Are Chinese EV Stocks NIO, XPEV, LI on Watch Today?
Via InvestorPlace
Why Is ProQR (PRQR) Stock Up 83% Today?
Via InvestorPlace
SVB Leerink Maintains Outperform Rating for Mirati Therapeutics: Here's What You Need To Know
Via Benzinga
Why Mirati Therapeutics Shares Are Nosediving
Via Benzinga
BMO Capital Downgrades Mirati Therapeutics: Here's What You Need To Know
Via Benzinga
Why Is Mirati Therapeutics (MRTX) Stock Up Today?
Via InvestorPlace
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
Via Benzinga
Tesla To $235? Here Are 10 Other Price Target Changes For Wednesday
Via Benzinga
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Via Benzinga
What 10 Analyst Ratings Have To Say About Mirati Therapeutics
Via Benzinga
Where Mirati Therapeutics Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Another Competitor For Amgen As FDA Approves Mirati Therapeutics' KRAS Inhibitor For Lung Cancer Setting
Via Benzinga
Pinterest, Oracle And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Nasdaq, S&P 500 Futures Soar Amid Optimistic Expectations Concerning Nov. Inflation: Oracle, Tesla, Pinterest Among Early Movers
Via Benzinga
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
Via Investor's Business Daily
Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days
Via Investor's Business Daily
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Mirati Therapeutics Shares Are Getting Hammered Again Today
Via Benzinga
Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
Via Benzinga
Why Shares of Mirati Therapeutics Fell Wednesday
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.